

CLAIMS

1. A pharmaceutical composition comprising a compound comprising the tetrapeptide motif D/E-D/E-G/K-W, and a pharmaceutically acceptable carrier.
5
2. The pharmaceutical composition according to claim 1, wherein the tetrapeptide motif is DDGW.
3. Use of a compound comprising the tetrapeptide motif D/E-D/E-G/K-W for the
10 manufacture of a pharmaceutical composition for the treatment of conditions dependent on leukocyte migration.
4. Use according to claim 3 wherein the condition dependent on leukocyte migration is leukaemia.
15
5. Use according to claim 3 for the manufacture of a pharmaceutical composition for inhibiting the adhesion of progelatinases to β_2 -integrins.
6. Use of the compound comprising the tetrapeptide motif D/E-D/E-G/K-W for the
20 manufacture of a pharmaceutical composition for prophylaxis and treatment of conditions dependent on neutrophil migration.
7. Use according to claim 6 for the manufacture of a pharmaceutical composition for prophylaxis and treatment of inflammatory conditions.
25
8. Use according to any one of claims 3 to 7, wherein the tetrapeptide motif is DDGW.
9. A method for therapeutic or prophylactic treatment of conditions dependent on leukocyte migration, comprising administering to a mammal in need of such treatment a
30 compound comprising the tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting leukocyte migration.
10. A method for therapeutic or prophylactic treatment of conditions dependent on neutrophil migration, comprising administering to a mammal in need of such treatment

a compound comprising the tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting neutrophil migration.

11. A method for therapeutic or prophylactic treatment of leukaemia, comprising
5 administering to a mammal in need of such treatment a compound comprising the tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting leukaemia cell migration.

12. A method for therapeutic or prophylactic treatment of inflammatory conditions,
10 comprising administering to a mammal in need of such treatment a compound comprising the tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting neutrophil migration.

13. The method according any one of claims 9 to 12, wherein the tetrapeptide motif is
15 DDGW.